Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Surein Arulananda"'
Autor:
Sagun Parakh, Kathryn Lee, Jeremy Rodrigues, Paul Yates, Polly Hypatia Dufton, Elena Tarasenko, Katrina Midgley, Ray Kelly, Surein Arulananda
Publikováno v:
BMJ Open, Vol 14, Iss 1 (2024)
Introduction Cancer is predominantly a disease of older adults, with an increasing number of cancer diagnoses in individuals aged 65 or older. Multiple geriatric factors have been shown to impact patient outcomes in cancer treatment. However, oncolog
Externí odkaz:
https://doaj.org/article/a187c166cf784616bd6b8f5c03c643e8
Autor:
Yang Wang, M.B.B.S., Jared Mathai, M.B.B.S., Muhammad Alamgeer, M.B.B.S., DMedSci, Sagun Parakh, MbChB., PhD, Eldho Paul, PhD, Paul Mitchell, MbChB., MD, Surein Arulananda, M.B.B.S., PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100544- (2023)
Introduction: There are no clinically validated prognostic biomarkers in the management of extensive-stage SCLC (ES-SCLC). We explored the association between clinical characteristics and survival outcomes in patients with ES-SCLC treated with chemoi
Externí odkaz:
https://doaj.org/article/19897c683b364ac195d9c8c817d928b9
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100477- (2023)
Externí odkaz:
https://doaj.org/article/3589ce577d864b9695d7dafb3d1b497a
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an effective treatment for EGFR-mutant non-small-cell lung cancer (NSCLC), however most patients invariably relapse after a period of minimal residual
Externí odkaz:
https://doaj.org/article/0998d409689e4b1c8d6e1e1696e0b231
Autor:
Farzana Y. Zaman, Ashwin Subramaniam, Afsana Afroz, Zarka Samoon, Daniel Gough, Surein Arulananda, Muhammad Alamgeer
Publikováno v:
Cancers, Vol 15, Iss 9, p 2425 (2023)
Background: Liquid biopsy (LB) analysis using (ctDNA)/cell-free DNA (cfDNA) is an emerging alternative to tissue profiling in (NSCLC). LB is used to guide treatment decisions, detect resistance mechanisms, and predicts responses, and, therefore, outc
Externí odkaz:
https://doaj.org/article/f79b879fb79c44f6a90ec453726ce78b
Autor:
Surein Arulananda, Megan O’Brien, Marco Evangelista, Laura J. Jenkins, Ashleigh R. Poh, Marzena Walkiewicz, Trishe Leong, John M. Mariadason, Jonathan Cebon, Srividya B. Balachander, Justin R. Cidado, Erinna F. Lee, Thomas John, Walter D. Fairlie
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs targeting the BCL-2-regulated apoptosis pathway could kill MPM cell lines in vitro,
Externí odkaz:
https://doaj.org/article/ad883c64d8a746e29bfa7c2330196e64
Autor:
Surein Arulananda, Megan O’Brien, Marco Evangelista, Tiffany J. Harris, Nikita S. Steinohrt, Laura J. Jenkins, Marzena Walkiewicz, Robert J. J. O’Donoghue, Ashleigh R. Poh, Bibhusal Thapa, David S. Williams, Trishe Leong, John M. Mariadason, Xia Li, Jonathan Cebon, Erinna F. Lee, Thomas John, W. Douglas Fairlie
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/768c48b448e544079fe397dafe8d4bf3
Autor:
Laura J. Jenkins, Ashleigh R Poh, W.D. Fairlie, Marco Evangelista, Erinna F. Lee, Srividya B. Balachander, John M. Mariadason, Trishe Leong, Megan O'Brien, Jonathan Cebon, Surein Arulananda, Justin Cidado, Thomas John, Marzena Walkiewicz
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-9 (2021)
Cell Death Discovery
Cell Death Discovery
Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs targeting the BCL-2-regulated apoptosis pathway could kill MPM cell lines in vitro, and contr
Publikováno v:
Expert Review of Anticancer Therapy. 21:413-424
Introduction: With limited recent therapeutic changes, malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancie...
Autor:
Gabrielle Lie, Thomas John, Leighton G Kearney, Andrew Weickhardt, Que Lam, David F L Liew, Surein Arulananda
Publikováno v:
Transl Lung Cancer Res
Malignant pleural mesothelioma (MPM) remains a deadly disease with limited therapeutic options beyond platinum/pemetrexed chemotherapy. Immune checkpoint inhibitors have demonstrated modest benefit in the second to later-line settings. An MPM patient